ERBB2 and gastric cancer: This is an impactful finding for a non-neglectable proportion of GC patients (14–21% of CD44v6_3+ cases) from either cohort, since up until now, only HER2 overexpression and microsatellite instability were widely accepted as therapy response markers in GC [4,8].